← All trials
NCT05050188
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 24, 2021
- Primary completion
- Sep 18, 2021
- Completion date
- Sep 25, 2021
- First posted
- Sep 20, 2021
- Last posted
- Sep 20, 2021
- Enrollment
- 24
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiangsu Carephar Pharmaceutical Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.